Willamette Valley Cancer Institute and Research Center

Running trials

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

  NCT07637578· Phase 2· SCRI Development Innovations, LLC· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  NCT07095452· Phase 2/3· AbbVie· Source

• Recruiting

  Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

  NCT07315113· Phase 1· Nuvectis Pharma, Inc.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Genmab· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Active, not recruiting

  BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

  NCT06773910· Phase 2· SCRI Development Innovations, LLC· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· Phase 1· AbbVie· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

  NCT06524375· Phase 2· Genentech, Inc.· Source

• Recruiting

  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT06428019· Phase 3· AbbVie· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

• Active, not recruiting

  A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

  NCT05963074· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

  NCT06163430· Phase 1/2· Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

• Recruiting

  A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT05650632· Phase 1· AbbVie· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· AbbVie· Source

• Recruiting

  MYLUNG Consortium Part 3: Observational Study

  NCT05885698· US Oncology Research· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

  NCT05451810· Phase 2· Genmab· Source

• Active, not recruiting

  Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

  NCT04782687· Phase 2· US Oncology Research· Source

• Active, not recruiting

  Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

  NCT04662255· Phase 3· Loxo Oncology, Inc.· Source

• Active, not recruiting

  Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT04666038· Phase 3· Loxo Oncology, Inc.· Source

• Active, not recruiting

  MYLUNG Consortium Study Protocol 2

  NCT05644808· US Oncology Research· Source

• Active, not recruiting

  A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

  NCT04625270· Phase 2· Verastem, Inc.· Source

• Recruiting

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

  NCT04401748· Phase 3· AbbVie· Source

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· CanariaBio Inc.· Source

• Active, not recruiting

  A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

  NCT04224493· Phase 3· Epizyme, Inc.· Source

• Active, not recruiting

  Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954· Phase 3· NSABP Foundation Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Multiple myeloma4 recruiting
• Myeloproliferative neoplasms2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

  NCT05198804· Phase 1/2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source

• Completed

  Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

  NCT04813627· BioNTech SE· Source

• Completed

  Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

  NCT03872947· Phase 1· Toray Industries, Inc· Source

• Completed

  Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

  NCT03884101· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

  NCT03646123· Phase 2· Seagen Inc.· Source

• Terminated

  A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

  NCT03582033· Phase 1· Seagen Inc.· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· NovoCure Ltd.· Source

• Completed

  Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

  NCT03424603· Phase 1· Sutro Biopharma, Inc.· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Incyte Corporation· Source

• Terminated

  A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

  NCT03173092· Phase 4· Takeda· Source

• Completed

  Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

  NCT03040999· Phase 3· Merck Sharp & Dohme LLC· Source